Sanofi-Aventis has told the U.S. Food and Drug Administration its rimonobant antiobesity drug, also known under the Acomplia brand, brings a higher risk of suicidal thoughts than placebo and does not recommend the treatment for patients suffering from major depression. The potential blockbuster received a previous setback in April when the FDA extended its review of the drug by three months to July 27, and its Endocrinologic and Metabolic Drugs Advisory Committee is due to meet Wednesday to review Rimonobant, provisionally branded Zimulti in the U.S.
Original post by Andrew K. Burger and software by Elliott Back
